Ginger Gregory - Biogen President
| BIIB Stock | MXN 3,250 228.71 6.57% |
President
Dr. Ginger Gregory, Ph.D. is Chief Human Resource Officer, Executive Vice President of Biogen Inc. since July 2017. Prior to joining Biogen, Dr. Gregory served as Executive Vice President and Chief Human Resources Officer at Shire PLC, a global specialty biopharmaceutical company, from February 2014 to April 2017. Prior to that, Dr. Gregory held executivelevel human resources positions for several multinational companies across a variety of industries, including Dunkin Brands Group Inc., a restaurant holding company, where she served as Chief Human Resource Officer Novartis, AG, a pharmaceutical company, where she was the division head of Human Resources for Novartis Vaccines and Diagnostics, Novartis Consumer Health and Novartis Institutes of BioMedical Research from 2005 to 2012 and Novo Nordisk AS, a pharmaceutical company, where she served as Senior Vice President, Corporationrationrate People Organization at the companys headquarters in Copenhagen, Denmark. Earlier in her career, Dr. Gregory held a variety of human resources generalist and specialist positions at BMS, a pharmaceutical company, and served as a consultant with Booz Allen Hamilton, an information technology consulting company, in the area of organization change and effectiveness. since 2017.
| Age | 55 |
| Tenure | 7 years |
| Phone | 617 679 2000 |
| Web | https://www.biogen.com |
Ginger Gregory Latest Insider Activity
Tracking and analyzing the buying and selling activities of Ginger Gregory against Biogen stock is an integral part of due diligence when investing in Biogen. Ginger Gregory insider activity provides valuable insight into whether Biogen is net buyers or sellers over its current business cycle. Note, Biogen insiders must abide by specific rules, including filing SEC forms every time they buy or sell Biogen'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Ginger Gregory over six months ago Disposition of 634 shares by Ginger Gregory of Biogen at 240.98 subject to Rule 16b-3 |
Biogen Management Efficiency
The company has return on total asset (ROA) of 0.076 % which means that it generated a profit of $0.076 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2023 %, meaning that it generated $0.2023 on every $100 dollars invested by stockholders. Biogen's management efficiency ratios could be used to measure how well Biogen manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Sara Greenstein | United States Steel | 44 | |
| Pipasu Soni | United States Steel | 45 | |
| Scott Buckiso | United States Steel | 51 | |
| Douglas Matthews | United States Steel | 53 | |
| Robert Jordan | Southwest Airlines | 62 | |
| David Wichmann | UnitedHealth Group Incorporated | 56 | |
| Tammy Romo | Southwest Airlines | 61 | |
| Christine Breves | United States Steel | 62 | |
| Thomas Roos | UnitedHealth Group Incorporated | 50 | |
| Michael Ven | Southwest Airlines | 61 | |
| Robert Telesmanic | Cognizant Technology Solutions | 56 | |
| James Bruno | United States Steel | 57 | |
| Marianne Short | UnitedHealth Group Incorporated | 68 | |
| Duane Holloway | United States Steel | 50 | |
| Richard Fruehauf | United States Steel | 51 | |
| Srinivasan Veeraraghavachary | Cognizant Technology Solutions | 63 | |
| John Rex | UnitedHealth Group Incorporated | 61 | |
| Andrew Watterson | Southwest Airlines | 56 | |
| Andrew Iaboni | McEwen Mining | 41 | |
Management Performance
| Return On Equity | 0.2 | |||
| Return On Asset | 0.076 |
Biogen Inc Leadership Team
Elected by the shareholders, the Biogen's board of directors comprises two types of representatives: Biogen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biogen. The board's role is to monitor Biogen's management team and ensure that shareholders' interests are well served. Biogen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biogen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christopher Viehbacher, CEO Pres | ||
| Robin Kramer, Chief Accounting Officer, Vice President | ||
| Sanjay Jariwala, Senior Vice President - Worldwide Medical | ||
| Ginger Gregory, Chief Human Resource Officer, Executive Vice President | ||
| Anabella Villalobos, Senior Vice President - Biotherapeutic & Medicinal Sciences (BTMS) | ||
| Susan Esq, Chief VP | ||
| Michael CPA, Ex CFO | ||
| Natacha Gassenbach, Chief Affairs | ||
| Nicole Murphy, Head Technology | ||
| Michael Hencke, Head Relations |
Biogen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biogen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.2 | |||
| Return On Asset | 0.076 | |||
| Profit Margin | 0.28 % | |||
| Operating Margin | 0.29 % | |||
| Current Valuation | 861.61 B | |||
| Shares Outstanding | 144 M | |||
| Shares Owned By Insiders | 0.68 % | |||
| Shares Owned By Institutions | 89.99 % | |||
| Price To Earning | 169.05 X | |||
| Price To Book | 3.30 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Biogen Stock Analysis
When running Biogen's price analysis, check to measure Biogen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biogen is operating at the current time. Most of Biogen's value examination focuses on studying past and present price action to predict the probability of Biogen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biogen's price. Additionally, you may evaluate how the addition of Biogen to your portfolios can decrease your overall portfolio volatility.